Novanta Inc. (NOVT)

Novanta Inc., together with its subsidiaries, provides precision medicine, precision manufacturing, medical solutions, robotics and automation solutions, and advanced surgery solutions in the United States and internationally. The company operates Automation Enabling Technologies and Medical Solutions segments. The Precision Medicine and Manufacturing segment designs, manufactures, and markets laser beam steering and scanning solutions, laser sources, robotic and precision motion, robotic end-of-arm tooling, and bearing spindles. This segment serves advanced industrial processes, advanced industrial and medical robotics, other medical and life science automation applications, and medical laser procedures, such as ophthalmology applications. The Medical Solutions segment provides a range of medical grade technologies, including medical insufflators, pumps, and related disposables; imaging, identification and RFID solutions; advanced motion control solutions; and light engines, and integrated operating room technologies. The company was formerly known as GSI Group, Inc. and changed its name to Novanta Inc. in May 2016. Novanta Inc. was incorporated in 1968 and is based in Bedford, Massachusetts.

• Jahresbericht (10-K)

  Ein jährlicher Überblick über das Geschäft, die Finanzergebnisse und die Risiken des Unternehmens.

  Eingereicht am 2026-02-23

  Dokument ansehen

• Quartalsbericht (10-Q)

  Ein Update zur finanziellen Entwicklung der letzten drei Monate.

  Eingereicht am 2026-08-05

  Dokument ansehen

• Ad-hoc-Meldung (8-K)

  Eine Mitteilung über ein wichtiges Ereignis, etwa einen Führungswechsel oder eine bedeutende Ankündigung.

  Eingereicht am 2026-08-05

  Dokument ansehen

• 3/4/2026POSITIVE
  Novanta Stock Has Underperformed This Past Year, but One Investor Just Made a $36 Million Bet on Shares

  Despite underperforming over the past year, Novanta Inc. (NOVT) has attracted a significant bet from an investor who purchased $36 million worth of shares. This bold move suggests strong conviction in the company's future recovery and growth potential. Novanta designs photonics and precision motion solutions for OEMs in medical and industrial markets globally. While the stock has lagged, this substantial investment could signal a turning point, indicating that the company's underlying value is underestimated by the market and may lead to a positive re-evaluation.

• 2/24/2026NEUTRAL
  Novanta (NOVT) Q4 2025 Earnings Call Transcript

  Markets Gazette notes the release of the earnings call transcript for Novanta Inc. (NOVT) concerning its fourth-quarter 2025 results. While specific financial figures and future projections have not yet been made public or analyzed herein, the availability of this document is a key event for investors. Earnings call transcripts provide direct insights into company performance, management strategies, challenges faced, and growth prospects, often revealing the tone and expectations of leadership. Shareholders and analysts will closely monitor this document for any implicit or explicit signals that could influence the stock's value in the short to medium term. The current lack of specific content necessitates a cautious approach, but the transcript remains a crucial resource for due diligence.

• 2/23/2026NEUTRAL
  A Preview Of Novanta's Earnings

  The Markets Gazette notes that investor focus is turning to Novanta Inc. ahead of its upcoming earnings release. The article, while providing no specific data, serves as a calendar marker for a key event that could define the stock's short-term trajectory. Analysts and the market are awaiting crucial figures such as revenue, earnings per share (EPS), and, most importantly, forward-looking guidance for the coming quarters. The stock's reaction will largely depend on how the actual results compare against consensus estimates. Until the official announcement, traders are likely to maintain a cautious stance, with trading volumes potentially increasing closer to the release date, signaling heightened anticipation.

• 2/22/2026NEGATIVE
  Is Novanta Stock a Buy or Sell After Its CEO Dumped 6,500 Shares?

  Novanta Inc., a leader in photonics and precision motion solutions for OEMs, has experienced notable insider selling. The CEO recently offloaded 6,500 shares, a move that could signal diminished confidence in the company's future performance from top management. While Novanta operates in promising tech sectors, this insider action might concern investors, suggesting the current stock price could be considered high or that potential challenges lie ahead not yet fully reflected in the market. Investors should closely watch upcoming financial reports and operational performance to assess the impact of this sale.